Table 3 Antimicrobial resistance profiles of CTX-M-producing Escherichia coli according to locations of acquisition and CTX-M types
Antimicrobial agent | Total (n = 139) | Hospital-onset (n = 60) | Community-onset | CTX-M type | ||||
|---|---|---|---|---|---|---|---|---|
Total (n = 79) | Healthcare-associated (n = 46) | Community-associated (n = 33) | CTX-M-14 (n = 69) | CTX-M-15 (n = 53) | CTX M-14 + M-15 (n = 17) | |||
Amikacin | 14 (10.1) | 7 (11.7) | 7 (8.9) | 3 (6.5) | 4 (12.1) | 4 (5.8) | 7 (13.2) | 3 (17.6) |
Gentamicin | 92 (65.5) | 45 (73.8) a | 47 (59.5) | 28 (60.9) | 19 (57.6) | 37 (53.6) | 40 (75.5)b | 15 (88.2)b |
Tobramycin | 94 (67.6) | 46 (76.7) | 48 (60.8) | 29 (63.0) | 19 (57.6) | 36 (52.2) | 43 (81.1)b | 15 (88.2) b |
Aztreonam | 130 (93.5) | 60 (100) | 70 (88.6) | 43 (93.5) | 27 (81.8) | 62 (89.9) | 51 (96.2) | 17 (100) |
Cefepime | 132 (95.0) | 58 (96.7) | 74 (93.7) | 44 (95.7) | 30 (90.9) | 65 (94.2) | 51 (96.2) | 16 (94.1) |
Ceftazidime | 77 (55.4) | 38 (63.9) | 39 (49.4) | 24 (52.2) | 15 (45.5) | 20 (29.0) | 43 (81.1)b | 14 (82.4) b |
Cefotaxime | 139 (100) | 60 (100) | 78 (100) | 46 (100) | 32 (100) | 69 (100) | 52 (100) | 17 (100) |
Ciprofloxacin | 105 (75.5) | 52 (86.7) a | 53 (67.1) | 34 (73.9) | 19 (57.6) | 47 (68.1) | 42 (79.2) | 16 (94.1)b |
Piperacillin-tazobactam | 33 (23.7) | 20 (33.3) a | 13 (16.5) | 7 (15.2) | 6 (18.2) | 11 (15.9) | 10 (18.9) | 12 (70.6) b,c |
Trimethoprim-sulfamethoxazole | 89 (64.0) | 38 (63.3) | 51 (64.6) | 29 (63.0) | 22 (66.7) | 52 (75.3) | 31 (58.5) b | 6 (35.3) b |
Multidrug resistance | 120 (86.3) | 53 (88.4) | 67 (84.8) | 39 (84.8) | 28 (84.8) | 55 (79.7) | 48 (90.6) | 17 (100)b |
Resistance scored ≥ 3 | 71 (51.1) | 39 (65.0) a | 32 (40.5) | 19 (41.3) | 13 (39.4) | 26 (37.7) | 31 (58.5) b | 14 (82.4) b |